Lexaria Bioscience Corp. Common Stock (LEXX)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of paying for a story when the accounting shows no earning power. Lexaria is a seven-employee biotech with a patented DehydraTECH delivery platform, but commercialization is minuscule. In FY2025, the year ended 2025-08-31, revenue was $705,923 and net loss was $11.9M; FY2024 revenue was $464,278 and net loss $5.8M; FY2023 revenue was $226,208 and net loss $6.7M. Annual revenue has grown from a tiny base, yet losses persist and widened in FY2025. More recently, fiscal Q2 2026, the quarter ended 2026-02-28, had revenue of $20,000 and a net loss of $1.4M; fiscal Q3 2026, the quarter ended 2026-05-31, had a net loss of $2.0M. Trailing free cash flow was -$7.5M, a -10.4% FCF yield against the $72.4M market cap at the 2026-10-26 close. The balance sheet shows low leverage with D/E 0.02, but low debt does not equal safety when cash burn is negative. FairStock's Piotroski score is 2/9, ROE is -162.77%, ROCE is -81.30%, and the P/E is -0.57 because there are no positive earnings to value; P/B is 1.02. The Lynch category is none because the company lost money in each of the last four years. A patent can be a moat only if it produces licensing revenue or product sales. Without that, the $72.4M market cap is a speculative option on future validation, not a Graham bargain.

In plain English: Lexaria is a small biotech that owns a drug-delivery technology and has almost no revenue while losing money. The business looks weak financially: losses continue, cash flow is negative, and revenue is tiny. At the recent $2.92 close, the $72.4 million market value looks expensive compared with those numbers, though the stock could be valued on future technology prospects rather than current profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-05-31) · fiscal Q2 2026 10-Q (period ended 2026-02-28) · fiscal Q1 2026 10-Q (period ended 2025-11-30) · fiscal Q3 2025 10-Q (period ended 2025-05-31) · FY2025 10-K (period ended 2025-08-31) · FY2024 10-K (period ended 2024-08-31) · FY2023 10-K (period ended 2023-08-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer